Chronic Spontaneous Urticaria

Dupixent notches seventh disease approval with urticaria nod

2 months ago talkbio0Tagged Approved, Chronic Spontaneous Urticaria, Dupixent, seventh, United States Food and Drug Administration, Urticaria

Dupixent, Chronic Spontaneous Urticaria, Approved, Urticaria, United States Food and Drug Administration, seventh

Third Harmonic Bio to Liquidate, Selling Key Urticaria Drug Asset THB335

2 months ago talkbio0Tagged biopharma exit strategy, Chronic Spontaneous Urticaria, clinical-stage, CSU, drug sales, Inhibitor, KIT, Kit device, shareholder, THB335, Third Harmonic Bio liquidation, value maximization

Third Harmonic Bio liquidation , THB335 drug sale , chronic spontaneous urticaria (CSU) , KIT inhibitor , biopharma exit strategy , clinical-stage biotech , shareholder value maximization

AAD25: Ahead of CSU filing, Novartis’ BTK inhibitor shows sleep benefits

3 months ago talkbio0Tagged Chronic Spontaneous Urticaria, CSU, Novartis, remibrutinib, Sleep

Chronic Spontaneous Urticaria, remibrutinib, Sleep, CSU, Novartis

Allakos Discontinues AK006 Development, Cuts 75% of Workforce Amid Strategic Restructuring

4 months ago talkbio0Tagged AK006, Allakos, Biotechnology, Chronic Spontaneous Urticaria, Failure (biologic function), Financial cost, phase 1 trial, restructuring, strategic alternatives

Allakos, AK006, workforce reduction, strategic alternatives, Phase 1 trial failure, chronic spontaneous urticaria (CSU), biotechnology, restructuring costs.